Germany / STADA’s Bold Bets on M&A
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into…
Address: Kurt-Georg-Kiesinger-Allee 3, Bonn 53173,Germany
Tel: +49 (0)228 99-307-0
Web: http://www.brarm.de/
The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) is an independent higher federal authority within the portfolio of the Federal Ministry of Health. The authority’s seat was transferred to Bonn in the course of the Government’s move to the capital. The BfArM is the successor to the Institute for Drugs (Institut für Arzneimittel) founded on 1 July 1975 as part of the now dissolved Federal Health Office (Bundesgesundheitsamt, BGA).Today, roughly 1000 employees – including physicians, pharmacists, chemists, biologists, technical assistants and administrative staff – work at the BfArM with the aim of preventing health risks by continuous improvement in the safety of medicinal products and by risk monitoring of medical devices as well as by monitoring the legal traffic in controlled substances scheduled in the UN-Conventions of 1961, 1971 and 1988.
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into…
German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant Pfizer on a COVID-19 vaccine. The company, founded by Professor Ugur Sahin in…
PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to unpack her important role within the global group and how Merck has pivoted to…
Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number of headline-grabbing investments in sites in its home market of Germany and…
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would ensure greater European access to innovative medicines and COVID-19 treatments. …
Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big new investments from Merck and Bayer, the implications of the country’s new Digital…
Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as the company increasingly looks toward cell and gene therapies to…
German giant Merck KGaA has announced a EUR one billion investment into its headquarters in Darmstadt, Germany up until 2025. The aim of Merck’s proposed investment is to secure…
As a majority family owned group, Merck is also the oldest pharmaceutical company in the world and known throughout the market for its long-term vision. How would you compare this…
The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth through acquisition in this extremely competitive and challenging global…
DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example…
Many companies that are focused in the diabetes segment have recognised the need to strengthen their operations in emerging markets, due to the increased prevalence of the disease in countries…
See our Cookie Privacy Policy Here
